{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T19:38:13Z","timestamp":1794598693451,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ophtha.2026.07.029","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:16:33Z","timestamp":1785770193000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Systemic Interleukin-6 Inhibition and Risk of Diabetic Retinopathy Development and Progression"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5216-639X","authenticated-orcid":false,"given":"Ahmed","family":"Abdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9465-8994","authenticated-orcid":false,"given":"Ahmed","family":"Alshaikhsalama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer F.","family":"Alsoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5097-110X","authenticated-orcid":false,"given":"Melissa","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-2780","authenticated-orcid":false,"given":"Lisa J.","family":"Faia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1087-9736","authenticated-orcid":false,"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2026.07.029_bib1","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ophtha.2026.07.029_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of diabetic retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib3","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.3390\/ijms19061816","article-title":"Diabetic retinopathy: pathophysiology and treatments","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ophtha.2026.07.029_bib4","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0161-6420(98)91020-X","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes","volume":"105","author":"Klein","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.07.029_bib5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2337\/dc11-1909","article-title":"Global prevalence and major risk factors of diabetic retinopathy","volume":"35","author":"Yau","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2026.07.029_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(18)30128-1","article-title":"Incidence and progression of diabetic retinopathy: a systematic review","volume":"7","author":"Sabanayagam","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American Diabetes Association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2026.07.029_bib8","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.08.001","article-title":"The progress in understanding and treatment of diabetic retinopathy","volume":"51","author":"Stitt","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2026.07.029_bib9","doi-asserted-by":"crossref","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.07.029_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","article-title":"IL-6 in inflammation, autoimmunity and cancer","volume":"33","author":"Hirano","year":"2021","journal-title":"Int Immunol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.exer.2018.09.009","article-title":"Inhibition of interleukin-6 trans-signaling prevents inflammation and endothelial barrier disruption in retinal endothelial cells","volume":"178","author":"Valle","year":"2019","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2026.07.029_bib12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0002-9394(01)01269-7","article-title":"Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema","volume":"133","author":"Funatsu","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib13","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/S0161-6420(03)00568-2","article-title":"Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema","volume":"110","author":"Funatsu","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.07.029_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12886-017-0572-6","article-title":"Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy","volume":"17","author":"Chen","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1080\/02713683.2019.1570274","article-title":"Interleukin-6 and diabetic retinopathy: a systematic review and meta-analysis","volume":"44","author":"Yao","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2026.07.029_bib16","article-title":"Interleukin-6 and macular edema: a review of outcomes with inhibition","volume":"24","author":"Yang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ophtha.2026.07.029_bib17","first-page":"1005","article-title":"Increased levels of IL-6, sIL-6R, and sgp130 in the aqueous humor and serum of patients with diabetic retinopathy","volume":"22","author":"Chen","year":"2017","journal-title":"Mol Vis"},{"key":"10.1016\/j.ophtha.2026.07.029_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101574","article-title":"Interleukin-6 trans-signaling inhibition prevents oxidative stress in a mouse model of early diabetic retinopathy","volume":"34","author":"Robinson","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib19","first-page":"1003","article-title":"Interleukin 6 has a critical role in diabetes-induced retinal vascular inflammation and permeability","volume":"52","author":"Rojas","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2026.07.029_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40259-023-00634-1","article-title":"Targeting IL-6 or IL-6 receptor in rheumatoid arthritis: what have we learned?","volume":"38","author":"Avci","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.ophtha.2026.07.029_bib22","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","article-title":"FDA approval: Siltuximab for the treatment of patients with multicentric Castleman disease","volume":"21","author":"Deisseroth","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ophtha.2026.07.029_bib23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.ophtha.2026.07.029_bib24","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: a review in rheumatoid arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.ophtha.2026.07.029_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10456-025-10022-8","article-title":"IL-6 trans-signaling: an overlooked driver of retinal neovascularization?","volume":"29","author":"Jung","year":"2025","journal-title":"Angiogenesis"},{"key":"10.1016\/j.ophtha.2026.07.029_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74203-9","article-title":"The role of IL-6-174 G\/C polymorphism and intraocular IL-6 levels in the pathogenesis of ocular diseases: a systematic review and meta-analysis","volume":"10","author":"Ulhaq","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2026.07.029_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.oret.2025.06.014","article-title":"Analysis of aqueous interleukin-6 in diabetic retinopathy: a prospective, controlled trial of 328 eyes","volume":"10","author":"Manda","year":"2026","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2026.07.029_bib29","first-page":"3334","article-title":"Efficacy and safety of vamikibart in patients with diabetic macular edema: first results from the phase 2 ALLUVIUM trial","volume":"67","author":"Khanani","year":"2026","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2026.07.029_bib30","first-page":"3335","article-title":"Efficacy and safety of vamikibart in combination with ranibizumab in patients with DME: first results from the phase 2 BARDENAS trial","volume":"67","author":"Goldberg","year":"2026","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2026.07.029_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ophtha.2016.11.034","article-title":"Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy","volume":"124","author":"Wykoff","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2026.07.029_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00125-025-06617-x","article-title":"Improving medication adherence in type 2 diabetes: strategies for better clinical and economic outcomes","volume":"69","author":"Highton","year":"2026","journal-title":"Diabetologia"},{"key":"10.1016\/j.ophtha.2026.07.029_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000331","article-title":"Ocular side effects of antirheumatic medications: a qualitative review","volume":"5","author":"Castillejo Becerra","year":"2020","journal-title":"BMJ Open Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026005348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642026005348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:59:45Z","timestamp":1790279985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642026005348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S0161642026005348"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.07.029","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Interleukin-6 Inhibition and Risk of Diabetic Retinopathy Development and Progression","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}